ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injury
ARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best Invention
EINDHOVEN, the Netherlands, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 5:45pm December 19, 2024 -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that it has received de novo classification and authorization to market its ARC-EX System from the US Food and Drug Administration (FDA).
“With today’s FDA de novo classification and authorization to market the ARC-EX System in the US, a new era begins for people with chronic spinal cord injury. For the first time, there is an approved therapy shown to improve hand strength and sensation after chronic SCI,” said Dave Marver, CEO of ONWARD Medical. “No longer will people be sent home and told nothing can be done to help them regain these abilities after their injury. We hope this is the first of many therapies we will introduce to help people regain independence from paralysis and other movement disabilities.”
The ARC-EX System delivers programmed electrical stimulation through the skin to the spinal cord via electrodes placed on the back of the neck. The device is non-invasive and does not require surgery like other spinal cord stimulation devices.
“Regaining hand ability is the highest treatment priority for people with paralysis, five-fold higher than regaining all other abilities lost to injury,” said Chet Moritz, PhD, Professor of Rehabilitation Medicine at the University of Washington. “I believe the ARC-EX System will have a tremendous impact on the quality of life of people living with SCI. My clinical and research colleagues in the US are eager and excited to have access to this important breakthrough technology.”
Results of the Up-LIFT clinical study published in Nature Medicine showed that 90% of study participants improved strength or function, 87% reported improvement in quality of life, and benefits were observed up to 34 years post-injury. The study also reported less spasm frequency, improved sleep quality, and improved upper body sensation and sense of touch.1
“This approval represents a watershed moment for the SCI Community. For those living with SCI and paralysis, the wait for even a single therapy to enhance their health and quality of life has been long and arduous. Now, we believe this milestone signals the opening of the floodgates for future advancements,” says Maggie Goldberg, President & CEO of the Christopher & Dana Reeve Foundation. “The Reeve Foundation, along with our donors and supporters, has been steadfast in our commitment to this cause. Nearly 20 years ago, we recognized epidural stimulation as one of the most promising avenues in SCI research. Today, this historic approval affirms our belief that it is the beginning of more to come.”
Today’s FDA market authorization is for use of the ARC-EX System in clinics; home use authorization is anticipated in mid-2025. The Company plans to seek CE Mark certification to commercialize the ARC-EX System in Europe in early 2025, with authorization expected 2H 2025. The Company is developing a pipeline of technologies, including its investigational implantable ARC-IM System and its investigational ARC-BCI System, an implanted platform that uses a brain-computer interface (BCI) powered by artificial intelligence (AI).
For questions about the ARC-EX System and its availability in the US, visit survey.onwd.com/support.
About Spinal Cord Injury (SCI)
Spinal cord injury affects approximately seven million people worldwide, including more than 300,000 in the United States. Half of injuries result in tetraplegia, affecting function of all four limbs, and making everyday tasks like eating, grooming, or using a phone extraordinarily challenging. Beyond the immediate loss of motor and sensory function, individuals with SCI face numerous secondary complications such as incontinence, poor blood pressure regulation, and loss of sexual function. The economic impact is equally significant, with lifetime treatment costs for tetraplegia exceeding $5 million.2 Historically, these injuries have been considered permanent with limited options for functional recovery, particularly for those more than one-year post-injury.
About ARC-EX System
The ARC-EX System is a non-invasive neuromodulation technology consisting of an external stimulator and wireless programmer which stimulate the spinal cord via electrical pulses from electrodes placed on the back of the neck. The system parameters can be optimized for each patient's unique needs. The ARC-EX System is the first and only approved technology indicated to improve hand sensation and strength after chronic spinal cord injury. It was selected as a TIME Magazine Best Invention in 2024.
About ONWARD Medical
ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). In addition to the ARC-EX System, which is now cleared for commercial sale in the US, the Company is developing an implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD).
For Media Inquiries: Aditi Roy, VP Communications media@onwd.com
For Investor Inquiries: Amori Fraser, Finance Director investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).
Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.
1 *Moritz, Chet, et al. “Non-invasive spinal cord stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.” Nature Medicine. 2024. 2 NSCISC Traumatic Spinal Cord Injury Facts and Figures at a Glance (2023 SCI Data Sheet) and Company analysis.
